secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2026-05-13T20:05:25+00:00
Accession:  0001493152-26-022710
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics Q1 2026: cash $6.9M; R&D spend down to $0.4M; DTC skincare launch planned mid-2026
--------------------------------------------------------------------------------

- Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.
- R&D expenses fell to $0.4M from $1.3M YoY, reflecting reduced clinical spending; SG&A rose to $1.5M from $1.1M.
- Announced Tome skincare brand for DTC; first product (Foundational Treatment) expected to launch mid-2026.
- Hired Kyra Peckaitis as VP of Marketing to lead Tome brand; cash expected to fund operations into Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/0001493152-26-022710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer